BioPharmSignal logoBioPharmSignal

Biotech News

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana plc (NCNA)NuCana plcEarnings

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in

Related news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

View all latest news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-06-01 12:00 EST

NuCana Appoints Ian Webster as Chief Financial Officer

NCNANuCana plc2026-05-14 20:01 EST

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-03-19 20:01 EST

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NCNANuCana plc2026-01-06 13:00 EST

NuCana Appoints Theresa Bruce as Chief Operating Officer

Stock data

Close
1.52 USD
Market cap
8.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States